Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease

Neurology. 1998 Dec;51(6):1587-92. doi: 10.1212/wnl.51.6.1587.

Abstract

Objective: To determine the frequency and the linkage distribution of seven mutations at the polymorphic gene coding for the arylamine N-acetyl transferase (NAT2; EC 2.3.1.5) in 121 unrelated patients with sporadic PD and in 121 unrelated healthy volunteers.

Methods: The study was performed with mutation-specific PCR using genomic DNA obtained from blood of the probands.

Results: Comparison of the NAT2 genotypes of the overall PD patients and control subjects did not indicate statistically significant differences. However, patients with early-onset PD (onset before the age of 50 years, n=37) showed a higher frequency of slow-acetylation genotypes (78.4% patients) compared with both healthy control subjects (55.4%) and with late-onset (onset after 51 years of age, n=84) PD patients (54.8%). Such a difference was statistically significant (p < 0.015) and was the result of a homogeneous increase in the frequency of slow-acetylation alleles. All subgroups analyzed in the study were in Hardy-Weinberg equilibrium for mutations at the NAT2 gene.

Conclusions: Slow-acetylation-mutated alleles may be considered low-penetrance genes in early-onset PD pathogenesis, with a relative risk ratio for individuals with slow-acetylation genotype of 2.92 (95% CI, 1.26 to 6.78). This study provides evidence for the interaction of genetic and environmental factors in the etiology of sporadic PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Alleles
  • Arylamine N-Acetyltransferase / genetics*
  • Female
  • Gene Deletion
  • Gene Expression Regulation, Enzymologic
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Parkinson Disease / genetics*
  • Polymorphism, Genetic*

Substances

  • Arylamine N-Acetyltransferase
  • NAT2 protein, human